This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

Continue >
The eMC  

You are viewing: Domperidone maleate

In May 2014, the MHRA issued the following information:

Domperidone (Motilium) is associated with a small increased risk of serious cardiac side effects. Its use is now restricted to the relief of nausea and vomiting and the dosage and duration of use have been reduced. It should no longer be used for the treatment of bloating and heartburn. Domperidone is now contraindicated in those with underlying cardiac conditions and other risk factors (see below). Patients with these conditions and patients receiving long-term treatment with domperidone should be reassessed at a routine appointment, in light of the new advice

Further information is available on the MHRA website

http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON418518

An information sheet for patients has also been issued

http://www.mhra.gov.uk/home/groups/dsu/documents/publication/con418525.pdf

The information in this Medicine Guide for Domperidone maleate varies according to the condition being treated and the particular preparation used.

To select information about the condition and preparation in which you are interested, click on the appropriate link below.

All conditions for Domperidone maleate